Returning guest, Dr. Kendra Grubb, surgical director of the Structural Heart and Valve Center at Emory Healthcare in Atlanta discusses Medtronic’s announcement of early results from the OPTIMIZE PRO clinical study at the Society for Cardiovascular Angiography & Interventions (SCAI) 2021 Scientific Sessions. The study evaluated procedure-related techniques and care pathways when using the self-expanding, supra-annular Evolut™ PRO and PRO+ TAVR systems in patients with symptomatic severe aortic stenosis.
Dr. Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. Prior to joining Emory, Dr. Grubb was the director of minimally invasive cardiac surgery and the surgical director of the heart valve program at the University of Louisville. Dr. Grubb is a champion for women’s heart disease, and is dedicated to improving the lives of all patients, both male and female, through innovation and by building collaborative teams to promote a patient-centered approach to the treatment of cardiovascular disease.Dr. Grubb has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy, and the GORE® conformable TAG® thoracic endoprosthesis for the primary treatment of aneurysms of the descending thoracic aorta.Dr. Grubb attended the University of Southern California, where she received her MD degree from the Keck School of Medicine and her Master of Health Administration from the Sol Price School of Public Policy. She completed her general surgery residency at the University of Illinois at Chicago in 2010, her fellowship in cardiothoracic surgery at the University of Virginia in Charlottesville in 2012, and her fellowship in interventional cardiology and transcatheter therapies at New York Presbyterian/Columbia University Medical Center in 2013.